Literature DB >> 26950411

Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Rafael Scaf de Molon1,2, Chingyun Hsu1, Olga Bezouglaia1, Sarah M Dry3, Flavia Q Pirih4, Akrivoula Soundia1, Fernando Queiroz Cunha5, Joni Augusto Cirelli2, Tara L Aghaloo1, Sotirios Tetradis1,6.   

Abstract

Rheumatoid arthritis (RA), an autoimmune inflammatory disorder, results in persistent synovitis with severe bone and cartilage destruction. Bisphosphonates (BPs) are often utilized in RA patients to reduce bone destruction and manage osteoporosis. However, BPs, especially at high doses, are associated with osteonecrosis of the jaw (ONJ). Here, utilizing previously published ONJ animal models, we are exploring interactions between RA and ONJ incidence and severity. DBA1/J mice were divided into four groups: control, zoledronic acid (ZA), collagen-induced arthritis (CIA), and CIA-ZA. Animals were pretreated with vehicle or ZA. Bovine collagen II emulsified in Freund's adjuvant was injected to induce arthritis (CIA) and the mandibular molar crowns were drilled to induce periapical disease. Vehicle or ZA treatment continued for 8 weeks. ONJ indices were measured by micro-CT (µCT) and histological examination of maxillae and mandibles. Arthritis development was assessed by visual scoring of paw swelling, and by µCT and histology of interphalangeal and knee joints. Maxillae and mandibles of control and CIA mice showed bone loss, periodontal ligament (PDL) space widening, lamina dura loss, and cortex thinning. ZA prevented these changes in both ZA and CIA-ZA groups. Epithelial to alveolar crest distance was increased in the control and CIA mice. This distance was preserved in ZA and CIA-ZA animals. Empty osteocytic lacunae and areas of osteonecrosis were present in ZA and CIA-ZA but more extensively in CIA-ZA animals, indicating more severe ONJ. CIA and CIA-ZA groups developed severe arthritis in the paws and knees. Interphalangeal and knee joints of CIA mice showed advanced bone destruction with cortical erosions and trabecular bone loss, and ZA treatment reduced these effects. Importantly, no osteonecrosis was noted adjacent to areas of articular inflammation in CIA-ZA mice. Our data suggest that ONJ burden was more pronounced in ZA treated CIA mice and that RA could be a risk factor for ONJ development.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ANTIRESORPTIVE; BISPHOSPHONATES; COLLAGEN-INDUCED ARTHRITIS; ONJ; OSTEOCLASTS; OSTEONECROSIS OF THE JAWS; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2016        PMID: 26950411      PMCID: PMC4970902          DOI: 10.1002/jbmr.2827

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  69 in total

1.  Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws?

Authors:  Nicolau Conte Neto; Alliny de Souza Bastos; Rosemary Adriana Chierici-Marcantonio; Elcio Marcantonio
Journal:  Med Hypotheses       Date:  2011-08-31       Impact factor: 1.538

Review 2.  A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field.

Authors:  Matthew R Allen; Salvatore L Ruggiero
Journal:  Int J Oral Maxillofac Implants       Date:  2014 Jan-Feb       Impact factor: 2.804

3.  Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis.

Authors:  Seung-Geun Lee; Young-Eun Park; Sung-Hoo Park; Tae-Kyun Kim; Hyun-Ju Choi; Seong-Jun Lee; Sung-Il Kim; Sun-Hee Lee; Geun-Tae Kim; Joung-Wook Lee; Jun-Hee Lee; Seung-Hoon Baek
Journal:  Int J Rheum Dis       Date:  2012-04-12       Impact factor: 2.454

4.  Molecular mechanisms of glucocorticoid-induced osteoporosis.

Authors:  D Patschan; K Loddenkemper; F Buttgereit
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

5.  Obesity and Hyperlipidemia Modulate Alveolar Bone Loss in Wistar Rats.

Authors:  Juliano Cavagni; Isabel Cristina de Macedo; Eduardo José Gaio; Andressa Souza; Rafael Scaf de Molon; Joni Augusto Cirelli; Ana Lúcia Hoefel; Luiz Carlos Kucharski; Iraci Lucena da Silva Torres; Cassiano Kuchenbecker Rösing
Journal:  J Periodontol       Date:  2015-09-17       Impact factor: 6.993

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

8.  Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus.

Authors:  T M Zizic; C Marcoux; D S Hungerford; J V Dansereau; M B Stevens
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?

Authors:  Géraldine Lescaille; Amélie E Coudert; Vanessa Baaroun; Marie-José Javelot; Martine Cohen-Solal; Ariane Berdal; Patrick Goudot; Jean Azérad; Blandine Ruhin; Vianney Descroix
Journal:  J Rheumatol       Date:  2013-03-15       Impact factor: 4.666

View more
  12 in total

Review 1.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

2.  Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ).

Authors:  Ioannis Gkouveris; Danny Hadaya; Akrivoula Soundia; Olga Bezouglaia; Yee Chau; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2019-04-03       Impact factor: 4.398

3.  Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Mice.

Authors:  Ioannis Gkouveris; Danny Hadaya; Naseim Elzakra; Akrivoula Soundia; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2022-07-11       Impact factor: 6.390

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

5.  Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization.

Authors:  Claudia Cristina Biguetti; André Hergesel De Oliva; Kent Healy; Ramez Hassan Mahmoud; Isabela Do Carmo Custódio; Dulce Helena Constantino; Edilson Ervolino; Marco Antonio Hungaro Duarte; Walid D Fakhouri; Mariza Akemi Matsumoto
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

6.  Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Eri Ito; Tatsuaki Matsumoto; Atsushi Kimura; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Mayu Morita; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 7.  Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.

Authors:  Angelica Leticia Reis Pavanelli; Bruna Silva de Menezes; Erica Bianca Barbosa Pereira; Fabio Assuncao de Souza Morais; Joni Augusto Cirelli; Rafael Scaf de Molon
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

Review 8.  Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions.

Authors:  Rafael Scaf de Molon; Carlos Rossa; Rogier M Thurlings; Joni Augusto Cirelli; Marije I Koenders
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

9.  Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study.

Authors:  Rafael Scaf de Molon; Rogier M Thurlings; Birgitte Walgreen; Monique M Helsen; Peter M van der Kraan; Joni Augusto Cirelli; Marije I Koenders
Journal:  Mediators Inflamm       Date:  2019-10-31       Impact factor: 4.711

Review 10.  Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw.

Authors:  Lina He; Xiangyu Sun; Zhijie Liu; Yanfen Qiu; Yumei Niu
Journal:  Int J Oral Sci       Date:  2020-10-21       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.